Top-Rated Biotech Stocks

It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.

Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.

Here are five such stocks:

Company	Market Cap	% CAPS All-Star Bulls	CAPS Rating (Out of 5)	CAPS Research
Amgen (Nasdaq: AMGN)	$46.8 B	94.3%	****	AMGN
Genentech (NYSE: DNA)	$77.7 B	96.3%	****	DNA
Genzyme (Nasdaq: GENZ)	$17.4 B	95.1%	*****	GENZ
ViroPharma (Nasdaq: VPHM)	$697 M	98.3%	*****	VPHM
Gilead Sciences (Nasdaq: GILD)	$49.0 B	97.6%	*****	GILD

Source: Motley Fool CAPS, as of June 11, 2008.

Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.